Transgenic HLA Mouse Model Related Publications

Alexander J, Oseroff C, Sidney J, Wentworth P, Keogh E, Hermanson G, Chisari FV, Kubo RT, Grey HM, Sette A. (1997) Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J Immunol. 159(10):4753-61.

Alexander J, Oseroff C, Dahlberg C, Qin M, Ishioka G, Beebe M, Fikes J, Newman M, Chesnut RW, Morton PA, Fok K, Appella E, Sette A. (2002) A decaepitope polypeptide primes for multiple CD8+ IFN-γ and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol. 168(12):6189-98.

Alexander J, Oseroff C, Sidney J, Sette A. (2003) Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes. Hum Immunol. 64(2):211-23.

Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, Ting J, Peters B, Southwood S, Stewart B, Rodriguez-Carreno MP, Mothe B, Whitton JL, Sette A, Buchmeier MJ. (2006) Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol. 80(17):8351-61.

Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, Alexander J, Ting JP, Bui HH, Sette A, Buchmeier MJ. (2007) HLA-A2-restricted protection against lethal lymphocytic choriomeningitis. J Virol. 81(5):2307-17.

Botten J, Sidney J, Mothé BR, Peters B, Sette A, Kotturi MF. (2010) Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system. Microbiol Mol Biol Rev. 74(2):157-70.

Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, Alexander J, Kotturi MF, Sette A, Buchmeier MJ. (2010) A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol. 84(19):9947-56.

Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R. (2011) Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine. 29(4):754-62.

Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R. (2012) Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 6:12.

Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, El Bissati K, Zhou Y, Suzuki Y, Lee D, Woods S, Sommerville C, Henriquez FL, Roberts CW, McLeod R. (2012) Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum Immunol. 73(1):1-10.

Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, Krakover J, Murthy S, Huang M, Power S, Babé L, Dahlberg C, McKinney D, Sette A, Southwood S, Philip R, Newman MJ, Meheus L. (2008) Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol. 82(1):435-50.

Dubey JP, Ferreira LR, Martins J, McLeod R. (2012) Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality. Parasitology. 139(1):1-13.

Irwin MJ, Heath WR, Sherman LA. (1989) Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med. 170(4):1091-101.

Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, del Guercio MF, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A. (1999) Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol. 162(7):3915-25.

Kotturi MF, Botten J, Sidney J, Bui HH, Giancola L, Maybeno M, Babin J, Oseroff C, Pasquetto V, Greenbaum JA, Peters B, Ting J, Do D, Vang L, Alexander J, Grey H, Buchmeier MJ, Sette A. (2009) A Multivalent and Cross-Protective Vaccine Strategy against Arenaviruses Associated with Human Disease. PLoS Pathog. 5(12):e1000695.

Men Y, Miconnet I, Valmori D, Rimoldi D, Cerottini JC, Romero P. (1999) Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J Immunol. 162(6):3566-73.

McKinney DM, Skvoretz R, Livingston BD, Wilson CC, Anders M, Chesnut RW, Sette A, Essex M, Novitsky V, Newman MJ. (2004) Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol. 173(3):1941-50.

Oseroff C, Sette A, Wentworth P, Celis E, Maewal A, Dahlberg C, Fikes J, Kubo RT, Chesnut RW, Grey HM, Alexander J. (1998) Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. Vaccine. 16(8):823-33.

Pasquetto V, Bui HH, Giannino R, Banh C, Mirza F, Sidney J, Oseroff C, Tscharke DC, Irvine K, Bennink JR, Peters B, Southwood S, Cerundolo V, Grey H, Yewdell JW, Sette A. (2005) HLA-A*0201, HLA-A*1101, and HLA-B*0702 Transgenic Mice Recognize Numerous Poxvirus Determinants from a Wide Variety of Viral Gene Products. J Immunol. 175(8):5504-15. Erratum in: J Immunol, 175(12):8440.

Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, Shahabi V. (2009) A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res. 15(3):924-32.

Singh RAK, Barry MA. (2002) Generation of Genome-Wide CD8 T Cell Responses in HLA-A*0201 Transgenic Mice by an HIV-1 Ubiquitin Expression Library Immunization Vaccine. J Immunol. 168(1):379-91.

Tan TG, Mui E, Cong H, Witola WH, Montpetit A, Muench SP, Sidney J, Alexander J, Sette A, Grigg ME, Maewal A, McLeod R. (2010) Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine. 28(23):3977-89.

Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG. (2009) A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug Des Devel Ther. 2:17-24.

Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. (1991) Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med. 173(4):1007-15.

Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, Livingston BD. (2003) Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol. 171(10):5611-23.

Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, Kolla RV, De Silva AD, de Silva AM, Grey H, Peters B, Shresta S, Sette A. (2011) Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol. 187(8):4268-79.

Zhai MX, Chen F, Zhao YY, Wu YH, Li GD, Gao YF, Qi YM. (2015) Novel epitopes identified from efflux pumps of Mycobacterium tuberculosis could induce cytotoxic T lymphocyte response. PeerJ. 3:e1229.